Prioritizing the Patient Voice with Hybrid Clinical Trials

Prioritizing the Patient Voice with Hybrid Clinical Trials

Posted by Elizabeth Gargill on Tue, Mar 8, 2022

 

ICT-Social

New survey findings reveal the importance of offering patients choice when it comes to improving clinical trial diversity, access, and engagement.

Patients want options, or choice, when it comes to clinical trial participation. New data from a recent Study Voices survey reveals the impact choice can have on participation. The findings empower clinical trial sponsors to shift from traditional clinical trial models to hybrid models with confidence.

 

DOWNLOAD NOW

Choice-2-1

 

 

The survey reflects attitudes and perspectives of 2,078 men and women, representing a cross section of the general population—including a wide range of ages, ethnicities, and social backgrounds. It includes a percentage of individuals who have participated in a clinical trial.

 

Surprisingly, the findings do not show dramatic differences in attitudes and experiences based on demographic factors. Rather, they show differences based on personal preference and deliver a clear message to the industry that patients want and, in fact, need choice in their healthcare experience.

 

Hybrid clinical trials are a combination of remote and in-person participation. They offer sponsors an adaptive approach that can minimize barriers to participation and help improve enrollment of underrepresented populations. They offer patients increased access, convenience, and flexibility and, most importantly, choice. By leveraging hybrid solutions—such as telehealth or medication delivery—that align with individual needs and preferences, clinical trial sponsors can reach and engage patients where they are in their daily lives

Click here to read the full article in International Clinical Trials.

Note: Taken from International Clinical Trials February 2022, pages 14-20. © Samedan Ltd.

Topics: Most Viewed, Study Voices, Aaron Fleishman, International Clinical Trials, Surveys, Hybrid Clinical Trials